Franziska Kohl
BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles.
Journal: Journal of extracellular vesicles
Published: December 15, 2025
Hybrid Extracellular Vesicles for Efficient Loading and Functional Delivery of mRNA.
Journal: Journal of extracellular vesicles
Published: April 11, 2025
Identification of cell type-specific cell-penetrating peptides through in vivo phage display leveraged by next generation sequencing.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 26, 2024
Barcoded Hybrids of Extracellular Vesicles and Lipid Nanoparticles for Multiplexed Analysis of Tissue Distribution.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 10, 2024
Correction: Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells.
Journal: Angiogenesis
Published: June 26, 2024
Epigenetic regulation by polycomb repressive complex 1 promotes cerebral cavernous malformations.
Journal: EMBO molecular medicine
Published: February 19, 2024
In vivo phage display identifies novel peptides for cardiac targeting.
Journal: Scientific reports
Published: January 24, 2024
Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 23, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026